3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
7
Phase 1
4
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Leukemia
6
Neuroblastoma
4
Lymphoma
4
Leukemia, Myeloid, Acute
4
Melanoma
3
Sarcoma
2
Rhabdomyosarcoma
2
Radiation Injuries
2
Malignant mesenchymal tumor
2
Lymphoma, Follicular
2
Leukemia, Myelomonocytic, Acute
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia, Monocytic, Acute
2
Leukemia, Megakaryoblastic, Acute
2
Leukemia, Erythroblastic, Acute
2
Head and Neck Neoplasms
2
Congenital Abnormalities
2
Breast Neoplasms
2
Uveal Melanoma
1
Urinary Bladder Neoplasms
1
Tongue Neoplasms
1
Stomatitis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Neoplasm Metastasis
1
Nasopharyngeal Neoplasms
1
Interventions
Temozolomide
8
Radiotherapy
6
Procarbazine
4
Radiation
3
Lomustine
3
Carmustine
3
Dihematoporphyrin Ether
2
sargramostim
1
rindopepimut
1
depatuxizumab mafodotin
1
Vincristine
1
Surgical Procedures, Operative
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy, Conformal
1
Radiosurgery
1
Photons
1
O(6)-benzylguanine
1
Neoadjuvant Therapy
1
Methylphenidate
1
Magnetic Resonance Spectroscopy
1
Leflunomide
1
Isotretinoin
1
Immunoglobulin G
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Fentanyl
1
Donepezil
1
Disulfides
1
DNA Methylation
1
Chemotherapy, Adjuvant
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Gliosarcoma
×
sargramostim
×
Clear all
NCT01480479
2018-01-16
ACT IV
Celldex Therapeutics
Phase 3
Completed
745 enrolled